Phibro Animal Health Corporation delivered a strong second quarter, with net sales increasing by 21% to $373.9 million and net income surging by $24.3 million to $27.5 million. Adjusted EBITDA also saw a significant rise of 41% to $68.1 million, primarily driven by the faster-than-expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings.
Net sales increased by 21% to $373.9 million, driven by strong performance in Animal Health.
Net income surged by $24.3 million to $27.5 million, reflecting favorable gross profit and improved foreign currency results.
Adjusted EBITDA increased by 41% to $68.1 million, primarily due to higher sales and gross profit in Animal Health.
The company raised its fiscal year 2026 guidance, anticipating net sales between $1.45 billion and $1.50 billion and adjusted EBITDA between $245 million and $255 million.
Phibro Animal Health Corporation has raised its fiscal year 2026 guidance, anticipating strong growth in net sales, net income, diluted EPS, and Adjusted EBITDA.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance